아포모르핀 염산염 시장 보고서 : 동향, 예측 및 경쟁 분석(-2035년)

Apomorphine Hydrochloride Market

The future of the global apomorphine hydrochloride market looks promising with opportunities in the hospital, clinic, and homecare setting markets. The global apomorphine hydrochloride market is expected to reach an estimated $439 million by 2035 from $324 million in 2027 with a CAGR of 3.9% from 2027 to 2035. The major drivers for this market are the increasing prevalence of parkinson's disease, the rising demand for advanced motor therapies, and the growing focus on injectable treatments.

• Lucintel forecasts that, within the dosage form category, pen devices is expected to witness the highest growth over the forecast period due to more convenience and accuracy in dosing with pen devices.
• Within the end use category, homecare settings is expected to witness the highest growth over the forecast period due to more self-administration at home of Parkinson's disease medication.
• In terms of regions, APAC is expected to witness the highest growth over the forecast period due to more cases of Parkinson's disease and the increasing accessibility of the healthcare system.

Emerging Trends in Apomorphine Hydrochloride Market

The Outlook for Apomorphine hydrochloride for 2025-2027 expects a shift away from rescue injections. Look for advances in patient-controlled, continuous and flexible therapies for the treatment of Parkinson's disease. The growth of the patient population as a result of the aging 'boomer' population, along with improvement in home health care and the design of medical devices is increasing the demand for Parkinson's disease therapies. The cost of therapy and the complexity of the administration process remain barriers for the reimbursement of Parkinson's disease therapies. Lucintel has identified innovations in the formulation and design of Parkinson's disease therapies as the key elements of competition.

• Patient-centric Delivery: The growing number of patients with Parkinson's disease (10 million) along with the need for timely treatment (less than one hour) means that the current technology and design of therapies is limiting. It is expected that in the near term (3-5 years) advances in therapy and design will enable Parkinson's disease treatments to be administered outside of medical facilities.
• Continuous Therapy: A primary goal of therapy for Parkinson's disease is to provide treatment during off periods. This can be accomplished using programmable therapies to replace rescue therapies.
• Digital Monitoring: Objective data on patient movement is becoming available beyond patient diaries, and neurologists are taking notice. The use of electronic devices in the home (i.e. electronic pens, wearables, and remote-monitoring devices for titrating injections) is expected to increase in the next five years. Digital forms of patient monitoring are expected to shorten the time required for patient adjustment (i.e. dose-adjustment intervals) and improve compliance. From a business perspective, the device will be quite appealing in a short time-frame.
• Focus on Movement Disorders: For the time being, it is expected that only movement disorder specialists will be authorized to prescribe these drugs and treatments due to potential side effects (i.e. nausea, hypotension, and dyskinesia, as well as injection site reactions) that require close observation. It remains likely that treatment pathways will include the use of antiemetics in 2025. How quickly these treatments are adopted by movement disorder specialists will depend on the availability of home-based nursing and other specialist-education programs.
• Dual Supply: Manufacturers of medical devices have focused more on the use of dual supply for medical device components since 2025. Due to the small volume of production of active pharmaceutical ingredients of apomorphine, it is expected that quality failures will adversely impact access to this medication. It is expected that failures in the supply of medical devices will continue to occur through 2030. Companies that produce a more patient-friendly device, and ensure reliable supply and adequate reimbursement will be able to defend a reasonable price for their medical device.

As of 2025, the movement disorder specialists maintain the monopoly on the prescription and administration of these treatments, due to the nature of many of the side effects including nausea, hypotension, dyskinesia, and injection site reactions. Antiemetic medications continue to be a part of many treatment pathways, and specialize in the titration of the treatment. Educating and training movement disorder specialists and home health nurses will likely drive the extension of the use of these treatments to other neurologists.

Recent Developments in the Apomorphine Hydrochloride Market

Apomorphine hydrochloride market activity will become more restrictive between 2025 and 2027. Companies will concentrate on ease of delivery through specialty neurology distribution channels and evidence for continuous infusion. In the opinion of Lucintel, the market will witness disciplined and focused development and manufacturing of apomorphine for the treatment of Parkinson's disease.

• Delivery System Innovation: Sponsors have advanced infusion pumps and other automating systems to reduce the burden of preparation. A pipeline update in 2025 identified more than 10 different devices and formulations of apomorphine (March 2025). In the next 3-5 years, individuals outside movement disorder centers are likely to utilize the device to manage patients with advanced Parkinson's disease.
• Market Specialization: Distributors have narrowed the channels of distribution and focused on the specialist markets. In 2023, the sole supplier of apomorphine in the US, Supernus, withdrew from the market, and in 2025, focus was on infusion-based products. Concentration of the market will be on suppliers with the ability to secure and utilize specialist distribution.
• Clinical Evidence Expansion: New evidence is emerging in clinical research that focuses on patient independence, persistence of treatment and duration of patient "off" time, in addition to the traditional endpoints of treatment response. In 2025, the Parkinson's disease registry reported > 20 studies evaluating apomorphine. Better evidence in the real world will impact the recommendations by professional societies and affect reimbursement by payers.
• Manufacturing Resilience: Supply of injectable Parkinson's disease treatments is anticipated to improve as pharmaceutical companies enhance their capacity to produce sterile injectables. Reliable supplier sources will allow hospitals to avoid using products that pose a risk of sudden discontinuity of supply.
• Regulatory Pathway Refinement: Agencies reviewing medical devices are requesting additional data supporting the usability of the devices and comparative evidence for certain advanced Parkinson's disease treatments. This, in addition to the increasing body of evidence, will enable the development of competitor products and accelerate the time to market for those products.

There is untapped potential in the advanced Parkinson's disease market. The first products to address the unmet need for reliable rescue and continuous treatments will dominate the market. It is likely that the most favorable products will incorporate a delivery device, special shipping and storage supplies, and special reimbursement justification.

Strategic Growth Opportunities in the Apomorphine Hydrochloride Market

The market for Apomorphine Hydrochloride is expanding as the prevalence of Parkinson's disease increases and limits of oral treatment continue. Manufacturers expect increasing demand for Apomorphine for home use for rescue and routine treatment by 2026. According to Lucintel, there is potential beyond traditional Apomorphine injection treatments. This is especially true where neurologists prefer more convenient treatments and means for controlling symptoms.

• New Delivery System: There are several potential new treatments and delivery methods for Apomorphine that that have a lower barrier to adoption. For example, the use of a pen injector to deliver treatment may reduce the burden of treatment for patients compared to traditional methods. According to the Parkinson's Foundation, there were over 10 million cases of Parkinson's Disease worldwide in March 2025. It is expected that in the next 3-5 years, treatment may shift from clinic-based to home-based.
• Premium Combination Therapy: There is an opportunity for combination Apomorphine-based treatments where one of the components of the combination is an anti-emetic. Currently, the majority of FDA-listed Apomorphine treatments are manufactured by only a few pharmaceutical companies. Therefore, unique and combine treatments may find success.
• Increased Focus on The Specialty Pharmacy Segment: Coordinated dispensing, training of nurses, and reimbursement services, have allowed the Company to develop a recurring revenue stream related to the specialty pharmacy segment. In June 2025, the Centres for Medicare and Medicaid Services (CMS) extended Part D of Medicare for certain Parkinson's Disease treatment drugs. CMS's action enabled thousands of Medicare plans to cover treatment drugs. In addition, specialty pharmacy coverage has been increasing. Specialty pharmacy coverage is expected to improve the likelihood that patients will adhere to their prescribed treatment.
• Growing Customer Base: There are currently a limited number of clinics specializing in the treatment of advanced Parkinson's Disease, and assisted living and home health care facilities. The National Parkinson's Foundation (NPF) reported in February 2025 that caregivers are assisting in the administration of medication to patients with Parkinson's Disease. In the next five years, companies that provide both treatment and training, may capture group purchasing organization (GPO) contracts.
• Use of Telemedicine: Symptoms of Parkinson's Disease may vary from patient to patient. Remote monitoring may assist in the management of the disease. In April 2025, an estimate by the World Health Organization indicated that 1% of the population over the age of 60, has Parkinson's Disease.

In addition to the competitive environment that exists for the supply of treatment drugs, the Company should expect competition for the training, monitoring and reimbursement services that it provides. The Company should direct its sales efforts to areas with aging populations. The use of remote monitoring of patients treated for Parkinson's Disease should be integrated to assist healthcare professionals to administer treatment and manage the patients in the community.

Apomorphine Hydrochloride Market Drivers and Challenges

Numerous trends such as innovations, shifts in the economy, and changes in the law can impact the market. Increased need for swift control of Parkinson's symptoms, improved drug delivery systems, and greater accessibility of specialists can also impact the market. There are also barriers to market growth including high costs to industry, regulatory barriers, and a lack of sufficient clinical facilities. According to Lucintel, the major trends affecting the market in the long-term are advancements in the field and increasing focus on patient care.

The factors responsible for driving this market include:

• Increasing Patient Need: More cases of Parkinson's disease result in greater need for rescue treatment. It is estimated that more than 10 million people worldwide will be diagnosed with Parkinson's by 2025. More awareness among the medical community is resulting in earlier recognition of motor fluctuations and avoidable shifts to off-state. The next several years will see improved diagnosis of the condition and more patient advocacy which will result in greater demand for treatment. While more people will be diagnosed with Parkinson's, the rate of treatment will be determined by the severity of the case and the availability of specialized care.
• Technology: Various recent advancements in technology, such as the development of better subcutaneous delivery devices and infusion pumps, have made innovative delivery systems for apomorphine hydrochloride easier to implement. New devices and delivery systems will facilitate more consistent and appropriate dosing and improve clinicians' abilities to recognize treatment response. By February 2025, connected medication management systems allowed the concurrent monitoring of multiple doses throughout the day, thus improving the ability to provide individualized care for patients with Parkinson's disease. In the next 3-5 years, the integration of tele-neurology, in combination with smart and responsive delivery systems, is expected to improve outpatient care by reducing treatment disruptions. The positive impact of new technologies is expected to be greatest in the areas where the biggest challenges are encountered in using traditional rescue therapies.
• Regulatory Environment: Continued and more focused guidance by regulatory agencies on the risks associated with medicinal products strengthened the manufacturers' commitment to improve apomorphine products and patient support programs. More transparent and defined requirements for various areas of pharmaceutical development and greater focus on pharmacovigilance and real-world data would help facilitate the development of safer and more innovative products. During the next 3-5 years, it is expected that the concern for patient safety, risks, and benefits would influence regulatory agencies to strengthen post market requirements. Manufacturers must continue to focus on the development of apomorphine products that are better and more innovative compared to currently available rescue medicinal products.
• Growing Diversity in Specialist Services: More movement-disorder clinics, telemedicine, specialized pharmacy and home-based services enhance the availability of apomorphine treatment. These services provide patients with support to manage the complexities of the treatment including, initial training and education, and management of adverse events and treatment refills. Throughout 2020-2025, telehealth services gained acceptance to provide health care services to patients with chronic conditions and strengthened the telehealth infrastructure to provide follow up to patients with neurological conditions. Increased availability of movement-disorder specialists will provide patients with more access to assessments and interventions to improve their symptoms of motor fluctuations. Funding and reimbursement for neurodegenerative conditions will drive market growth.
• Improved Product Offerings: Pharmaceutical companies invested to improve the formulation and production of apomorphine to reduce the complexity of the treatment and improve convenience. Advanced manufacturing processes and improved production systems increased the reliability and resilience of the supply of the pharmaceutical product. Manufacturers integrated process automation and improved devices to enhance the consistency of production systems. Improved manufacturing and product differentiation allowed companies to refine their pricing strategies and control the market. Focused on total cost of treatment, health care systems will encourage the use of apomorphine treatment for motor fluctuations. Improved convenience, user friendliness and reliability of the supply will facilitate broader adoption of the product.

The challenges facing this market include:

• Concerns Related To Safety and Tolerability: Apomorphine hydrochloride may cause vomiting and nausea, and may also cause dizziness, hypotension, and somnolence, as well as hallucinations. These may require use of antiemetics. There may also be a need for close supervision and patient education, adding to the complexity of the treatment. The 2025 Parkinson's disease treatment guidelines requested monitoring of Falling, and of Blood Pressure and Neuropsychiatric symptoms, due to the risks associated with the treatment. It is expected that in the next 3 to 5 years, there will be concern regarding the tolerance of the treatment amongst the target population.
• High Costs of The Treatment and Insufficient Reimbursement: Apomorphine hydrochloride is costly due to the need for ancillary services, such as visits by health professionals, and continued monitoring by a neurology specialist. In August 2025, it was reported that health-care systems across the world assessed other neuro-specialty medicines, resulting in fewer systems reimbursing the treatment. It is expected that in the next 3 to 5 years, the cost of the treatment would influence its acceptance in the markets with less developed economies.
• Moring The Infrastructure and Reliability of The Supply Chain: Reliable supply chains and well-developed clinical infrastructures enable best practice of apomorphine hydrochloride. These systems often do not exist, particularly in lower- and middle-income countries, and delays or complete absences in the supply of auxiliary and specialist equipment and medicinal products can disrupt treatment. Healthcare professionals have reported in 2025 and beyond the significance of having robust, flexible, and reliable supply chains because of the disruption in the global flow of medicines. In the next 3-5 years, the same conditions, including an absence of appropriate and adequately located healthcare and logistics infrastructure, will mean that most of the world's population will be beyond the reach of apomorphine hydrochloride treatment. Investment and joint commitments by the health sector will be needed for training and the use of telemedicine and other approaches to improve treatment access.

The market for apomorphine hydrochloride is projected to grow, especially in countries with a rising incidence of Parkinson's disease. The demand is also driven by the need to address motor fluctuations. Barriers including adverse effects, complexity and cost of the product will restrict growth. The development of new products to address the barriers will facilitate wider use of apomorphine hydrochloride. It is anticipated that the product most acceptable to the healthcare market will be one that integrates a new and improved means of product delivery with a favorable product cost.

List of Apomorphine Hydrochloride Market Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies apomorphine hydrochloride market companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the apomorphine hydrochloride market companies profiled in this report include-

• Supernus Pharmaceuticals
• Britannia Pharmaceuticals STADA
• Ever Pharma
• Evolan Pharma AB
• Tianjin Tianwei Pharmaceutical

Apomorphine Hydrochloride Market by Segment

The study includes a forecast for the global apomorphine hydrochloride market by dosage form, route of administration, application, end use, and region.

Apomorphine Hydrochloride Market by Dosage Form [Value ($M) from 2019 to 2035]:

• Injectable Solutions
• Pen Devices
• Oral Tablets

Apomorphine Hydrochloride Market by Route of Administration [Value ($M) from 2019 to 2035]:

• Subcutaneous Injection
• Intravenous Administration
• Oral Administration

Apomorphine Hydrochloride Market by Application [Value ($M) from 2019 to 2035]:

• Parkinson's Disease Treatment
• Erectile Dysfunction Treatment
• Off-Label Uses

Apomorphine Hydrochloride Market by End Use [Value ($M) from 2019 to 2035]:

• Hospitals
• Clinics
• Homecare Settings
• Others

Apomorphine Hydrochloride Market by Region [Value ($M) from 2019 to 2035]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Apomorphine Hydrochloride Market

The method of delivering apomorphine hydrochloride is evolving from rescue injections to continuous infusions. In February 2025, the US FDA approved Onapgo. The European agencies, however, did not amend their positions on pump-based therapy for Parkinson's. It is expected that from a commercial viewpoint, the primary factors driving the market between 2022 and 2027 will be the timeliness and adequacy of regulatory frameworks and integration of devices.

• United States: In February 2025, the US FDA approved the continuous subcutaneous infusion of apomorphine (Onapgo) for the rescue of acute Parkinsonian attacks. This infusion will be delivered by a wearable device. It is anticipated that, similar to other Parkinson's disease (PD) therapies, the approval of Onapgo will prompt the development of various device combinations.
• China: The Chinese National Medical Products Administration (NMPA) approved Chinese-made Apomorphine Hydrochloride Injection prior to 2025. Currently, manufacturers of this injection have limited their distribution to the hospital and Parkinson's disease treatment pharmacy channels. It is expected that by 2025, an indigenously manufactured injectable Apomorphine Hydrochloride would be available, and thereby reduce the reliance on imported Parkinson's disease treatments.
• Germany: Dacepton was commercially available in Germany via Parkinson's disease treatment centre networks in 2025. Germany is one of the major countries in the manufacturing and distributing of neurological medicinal products in the European Union. As it is available in the specialist market in Germany, it is expected that Germany will also play a major role in the supply of this product in the European Union.
• India: There was continued business-to-business (B2B) supply of apomorphine injections in India in 2025. Products were available in a 10 mg/mL concentration. There are sufficient local means to produce ampoules. It is expected that Parkinson's disease centres of higher medical care will be provided with this product.
• Japan: The major therapy for Parkinson's disease in Japan in 2025 was levodopa in various forms. There was no commercial availability of apomorphine in Japan in 2025. It is expected that a local country clinical study in Japan together with a regulatory and reimbursement assessment will dictate the time and means for commercial availability of apomorphine in Japan.

Features of the Global Apomorphine Hydrochloride Market

• Market Size Estimates: apomorphine hydrochloride market size estimation in terms of value ($B).
• Trend and Forecast Analysis: Market trends (2019 to 2026) and forecast (2027 to 2035) by various segments and regions.
• Segmentation Analysis: apomorphine hydrochloride market size by various segments, such as by dosage form, route of administration, application, end use, and region in terms of value ($B).
• Regional Analysis: apomorphine hydrochloride market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
• Growth Opportunities: Analysis of growth opportunities in different dosage forms, routes of administration, applications, end uses, and regions for the apomorphine hydrochloride market.
• Strategic Analysis: This includes M&A, new product development, and competitive landscape of the apomorphine hydrochloride market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the apomorphine hydrochloride market by dosage form (injectable solutions, pen devices, and oral tablets), route of administration (subcutaneous injection, intravenous administration, and oral administration), application (parkinson's disease treatment, erectile dysfunction treatment, and off-label uses), end use (hospitals, clinics, homecare settings, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 8 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Market Overview

• 2.1 Background and Classifications
• 2.2 Supply Chain

3. Market Trends & Forecast Analysis

• 3.1 Macroeconomic Trends and Forecasts
• 3.2 Industry Drivers and Challenges
• 3.3 PESTLE Analysis
• 3.4 Patent Analysis
• 3.5 Regulatory Environment

4. Global Apomorphine Hydrochloride Market by Dosage Form

• 4.1 Overview
• 4.2 Attractiveness Analysis by Dosage Form
• 4.3 Injectable Solutions : Trends and Forecast 2019 to 2035
• 4.4 Pen Devices : Trends and Forecast 2019 to 2035
• 4.5 Oral Tablets : Trends and Forecast 2019 to 2035

5. Global Apomorphine Hydrochloride Market by Route of Administration

• 5.1 Overview
• 5.2 Attractiveness Analysis by Route of Administration
• 5.3 Subcutaneous Injection : Trends and Forecast 2019 to 2035
• 5.4 Intravenous Administration : Trends and Forecast 2019 to 2035
• 5.5 Oral Administration : Trends and Forecast 2019 to 2035

6. Global Apomorphine Hydrochloride Market by Application

• 6.1 Overview
• 6.2 Attractiveness Analysis by Application
• 6.3 Parkinson's Disease Treatment : Trends and Forecast 2019 to 2035
• 6.4 Erectile Dysfunction Treatment : Trends and Forecast 2019 to 2035
• 6.5 Off-Label Uses : Trends and Forecast 2019 to 2035

7. Global Apomorphine Hydrochloride Market by End Use

• 7.1 Overview
• 7.2 Attractiveness Analysis by End Use
• 7.3 Hospitals : Trends and Forecast 2019 to 2035
• 7.4 Clinics : Trends and Forecast 2019 to 2035
• 7.5 Homecare Settings : Trends and Forecast 2019 to 2035
• 7.6 Others : Trends and Forecast 2019 to 2035

8. Regional Analysis

• 8.1 Overview
• 8.2 Global Apomorphine Hydrochloride Market by Region

9. North American Apomorphine Hydrochloride Market

• 9.1 Overview
• 9.2 North American Apomorphine Hydrochloride Market by Dosage Form
• 9.3 North American Apomorphine Hydrochloride Market by End Use
• 9.4 The United States Apomorphine Hydrochloride Market
• 9.5 Canadian Apomorphine Hydrochloride Market
• 9.6 Mexican Apomorphine Hydrochloride Market

10. European Apomorphine Hydrochloride Market

• 10.1 Overview
• 10.2 European Apomorphine Hydrochloride Market by Dosage Form
• 10.3 European Apomorphine Hydrochloride Market by End Use
• 10.4 German Apomorphine Hydrochloride Market
• 10.5 French Apomorphine Hydrochloride Market
• 10.6 Italian Apomorphine Hydrochloride Market
• 10.7 Spanish Apomorphine Hydrochloride Market
• 10.8 The United Kingdom Apomorphine Hydrochloride Market

11. APAC Apomorphine Hydrochloride Market

• 11.1 Overview
• 11.2 APAC Apomorphine Hydrochloride Market by Dosage Form
• 11.3 APAC Apomorphine Hydrochloride Market by End Use
• 11.4 Chinese Apomorphine Hydrochloride Market
• 11.5 Indian Apomorphine Hydrochloride Market
• 11.6 Japanese Apomorphine Hydrochloride Market
• 11.7 South Korean Apomorphine Hydrochloride Market
• 11.8 Indonesian Apomorphine Hydrochloride Market

12. ROW Apomorphine Hydrochloride Market

• 12.1 Overview
• 12.2 ROW Apomorphine Hydrochloride Market by Dosage Form
• 12.3 ROW Apomorphine Hydrochloride Market by End Use
• 12.4 Middle Eastern Apomorphine Hydrochloride Market
• 12.5 South American Apomorphine Hydrochloride Market
• 12.6 African Apomorphine Hydrochloride Market

13. Competitor Analysis

• 13.1 Product Portfolio Analysis
• 13.2 Operational Integration
• 13.3 Porter's Five Forces Analysis
  • Competitive Rivalry
  • Bargaining Power of Buyers
  • Bargaining Power of Suppliers
  • Threat of Substitutes
  • Threat of New Entrants
• 13.4 Market Share Analysis

14. Opportunities & Strategic Analysis

• 14.1 Value Chain Analysis
• 14.2 Growth Opportunity Analysis
  • 14.2.1 Growth Opportunity by Dosage Form
  • 14.2.2 Growth Opportunity by Route of Administration
  • 14.2.3 Growth Opportunity by Application
  • 14.2.4 Growth Opportunity by End Use
• 14.3 Emerging Trends in the Global Apomorphine Hydrochloride Market
• 14.4 Strategic Analysis
  • 14.4.1 New Product Development
  • 14.4.2 Certification and Licensing
  • 14.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

15. Company Profiles of the Leading Players Across the Value Chain

• 15.1 Competitive Analysis Overview
• 15.2 Supernus Pharmaceuticals
  • Company Overview
  • Apomorphine Hydrochloride Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 15.3 Britannia Pharmaceuticals STADA
  • Company Overview
  • Apomorphine Hydrochloride Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 15.4 Ever Pharma
  • Company Overview
  • Apomorphine Hydrochloride Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 15.5 Evolan Pharma AB
  • Company Overview
  • Apomorphine Hydrochloride Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 15.6 Tianjin Tianwei Pharmaceutical
  • Company Overview
  • Apomorphine Hydrochloride Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing

16. Appendix

• 16.1 List of Figures
• 16.2 List of Tables
• 16.3 Research Methodology
• 16.4 Disclaimer
• 16.5 Copyright
• 16.6 Abbreviations and Technical Units
• 16.7 About Us
• 16.8 Contact Us